Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France.
about
Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaHospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.One-unit versus two-unit cord-blood transplantation for hematologic cancers.Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors."No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment.Umbilical cord blood donation: public or private?Cord blood transplant for acute myeloid leukaemia.Advances in umbilical cord blood cell therapy: the present and the future.Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.Double vs. single cord blood transplantation in adolescent and adult hematological malignancies with heavier body weight (≥50 kg).Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia.Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.
P2860
Q28080943-2EE481F7-30EB-46DB-8E1E-0C1DC27D01EFQ34325220-60BC2289-E063-4C36-9FEE-A436395E4938Q34637605-E467F79B-340C-46DE-BF86-2AC54741A065Q35083562-6809F2D7-7002-496F-8EC6-248BA400C9F7Q36622322-451E9D9D-0778-4691-87DE-09EC25901FA2Q36675937-20FFB47D-0789-4A22-BCED-9AFEB3A02F8DQ37674034-6253BC02-11BD-4236-BF56-684603587130Q38510475-9751354B-188B-4564-8CAF-F19D9D1F7B7EQ38696346-1FF0FCFE-0B2A-458C-9359-4BAF5DB9F6BBQ38734758-9114D208-58B8-4412-8096-9E9D4B57D590Q38747929-24BB2C46-FFE4-4EDD-9359-89B1568004C8Q47195077-08A20F78-3335-4615-B45E-B52D04CE946BQ48199548-6706535F-D2AE-4270-8665-FF5677E8D1C3Q52896167-70562BE1-047A-408D-8AE1-A3F7B1FA0D45
P2860
Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness and clinica ...... with acute leukemia in France.
@en
Cost-effectiveness and clinica ...... with acute leukemia in France.
@nl
type
label
Cost-effectiveness and clinica ...... with acute leukemia in France.
@en
Cost-effectiveness and clinica ...... with acute leukemia in France.
@nl
prefLabel
Cost-effectiveness and clinica ...... with acute leukemia in France.
@en
Cost-effectiveness and clinica ...... with acute leukemia in France.
@nl
P2093
P2860
P50
P1433
P1476
Cost-effectiveness and clinica ...... with acute leukemia in France.
@en
P2093
Catherine Faucher
Chantal Kenzey
Didier Blaise
Dominique Bertrand
Eric Deconinck
Eurocord and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Federico Garnier
Fernanda Volt
Gerard Socié
Jean Yves Cahn
P2860
P304
P356
10.3324/HAEMATOL.2013.092254
P577
2013-10-18T00:00:00Z